Big Pharma Split Corp.
PRM.TOTSXFinancial Services● Active
$13.75
+$0.12(+0.88%)
Market Cap$17933259
P/E Ratio—
52W High$15.5
52W Low$10.71
Big Pharma Split Corp. (PRM.TO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRM.TO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $4.40M | ($0.54M) | ($0.65M) | $2.39M | $4.21M |
| Depreciation & Amort. | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Stock-Based Comp. | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Change in Working Capital | ($0.03M) | ($0.01M) | $0.01M | $0.18M | ($0.15M) |
| Net Cash from Operations | ($1.06M) | ($1.30M) | $11.86M | $1.13M | ($9.00M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00M) | $0.00M | ($0.00M) | $0.00M | $0.00M |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | ($0.47M) | ($5.32M) | $0.00M | $0.00M |
| Dividends Paid | ($1.51M) | ($1.50M) | ($2.11M) | ($2.62M) | ($2.84M) |
| Debt Issued / Repaid | $1.61M | $1.28M | ($5.49M) | $0.48M | $5.75M |
| Net Cash from Financing | $1.81M | ($0.35M) | ($12.47M) | ($1.74M) | $10.19M |
| Free Cash Flow | |||||
| Free Cash Flow | ($1.06M) | ($1.30M) | $11.86M | $1.13M | ($9.00M) |
| FCF Margin %(computed) | -72.58% | -70.06% | — | 28.74% | -167.94% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CAD · M
Explore more Big Pharma Split Corp. data
About Big Pharma Split Corp. (PRM.TO) Cash Flow Statement
Big Pharma Split Corp. generated operating cash flow of ($0.00B) and free cash flow of ($0.00B) for 2025 — a FCF margin of -72.58%. Capital expenditure was ($0.00B).
Frequently asked questions
PRM.TO · 4 questionsBig Pharma Split Corp. generated free cash flow of ($0.00B) for 2025, up 18.6% year-over-year.
PRM.TO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10